Why do TAM receptors protect against neuroinvasive viruses despite their known immunosuppressive role?

Novel Therapeutic Hypotheses: TAM Receptor Protection in Neuroinvasive Viral Infection

Background Synthesis

The paradox that Mertk/Axl deficiency increases neuroinvasive viral susceptibility despite TAM receptors' known immunosuppressive function suggests context-dependent, cell-type-specific, or temporally regulated protective mechanisms beyond canonical immunosuppression.

Hypothesis 1: Microglial Mertk-Driven Phagocytic Clearance of Viral Debris

Description: Microglial Mertk activation by GAS6 promotes efferocytosis and phagocytic clearance of virus-infected apoptotic cells, preventing secondary necrotic cell death and reducing CNS viral load. This protective function operates independently of immunosuppression and is critical for controlling neurotropic viral replication.

Target Gene/Protein: MERTK (microglia)

Supporting Evidence:

• Mertk is the primary TAM receptor governing microglial phagocytic function (PMID: 28714961)
• Microglial Mertk deficiency impairs clearance of apoptotic cells, exacerbating neuroinflammation (PMID: 26302268)
• TAM receptor activation enhances phagocytosis of pathogen-associated molecular patterns (PMID: 29101257)

Predicted Outcomes: Microglia-specific Mertk agonists would enhance viral clearance; Mertk-deficient microglia would show impaired WNV/ZIKV debris clearance and enhanced viral persistence.

Confidence: 0.62

Hypothesis 2: Axl-Mediated Amplification of Type I IFN Signaling in CNS

Description: Axl synergizes with type I interferon signaling through direct protein-protein interaction with IFNAR, amplifying intracellular STAT1/STAT2 phosphorylation. This enhanced autocrine IFN loop creates a heightened antiviral state specifically in CNS cells, explaining why Axl deficiency increases neuroinvasive disease despite TAM receptors' immunosuppressive labeling.

Target Gene/Protein: AXL (axl receptor tyrosine kinase)

Supporting Evidence:

• Axl forms a physical complex with IFNAR2 to enhance type I IFN signaling (PMID: 25437556)
• Gas6/Axl axis potentiates IFN-β responses in viral infection models (PMID: 27466488)
• Axl-deficient mice show impaired antiviral gene signatures during Zika infection (PMID: 29104231)

Predicted Outcomes: Axl agonists combined with IFN-β therapy would synergistically reduce viral titers in CNS; Axl-IFNAR binding mutants would fail to protect against neuroinvasion.

Confidence: 0.58

Hypothesis 3: Mertk-Driven MerTK Activation on Infiltrating Monocytes Limits Neurotoxic Polarization

Description: Infiltrating Ly6C^hi inflammatory monocytes express MerTK upon CNS entry. GAS6-Mertk signaling skews these monocytes toward an anti-inflammatory M2-like phenotype, reducing production of neurotoxic TNF-α and IL-1β while preserving viral clearance capacity. Deficiency leads to unchecked pro-inflammatory monocyte accumulation in the brain parenchyma.

Target Gene/Protein: MERTK (monocyte lineage)

Supporting Evidence:

• MerTK activation on macrophages drives M2 anti-inflammatory polarization (PMID: 27581050)
• Monocyte-derived cells are primary producers of neurotoxic cytokines in WNV encephalitis (PMID: 25372179)
• TAM receptor agonists promote IL-10 production while suppressing pro-inflammatory cytokines (PMID: 28428278)

Predicted Outcomes: GAS6 administration would reduce neurotoxic monocyte infiltration; MerTK-blocking antibodies would exacerbate neurological damage independent of viral load changes.

Confidence: 0.51

Hypothesis 4: Tyro3-Mediated Preservation of Neural Progenitor Cell Viability During Viral Infection

Description: Tyro3 is highly expressed on neural stem/precursor cells and protects against viral-induced apoptosis through activation of PI3K-AKT survival signaling. Tyro3 deficiency renders these cells vulnerable to death from bystander inflammation or direct viral infection, compromising neural repair capacity after encephalitis.

Target Gene/Protein: TYRO3 (Tyro3 receptor)

Supporting Evidence:

• Tyro3 deletion sensitizes hippocampal neurons to apoptotic cell death (PMID: 24648023)
• TAM receptor activation engages PI3K-AKT anti-apoptotic pathways (PMID: 26189796)
• Neurogenesis is impaired during West Nile virus infection, contributing to long-term sequelae (PMID: 28878135)

Predicted Outcomes: Tyro3 agonists would preserve NPC populations during infection; Tyro3^-/- mice would show greater neuronal loss and cognitive deficits post-infection.

Confidence: 0.44

Hypothesis 5: Temporal Switch Hypothesis — TAM Receptors Suppress Early Immunopathology but Enable Later Repair

Description: TAM receptors exhibit a biphasic protective function: early-phase immunosuppressive signaling (via SOCS1/3) limits excessive CNS infiltration and immunopathology, while later-phase activation promotes efferocytosis and repair programs. Deleting TAM receptors eliminates this temporal control, causing either insufficient early suppression OR failed resolution of inflammation.

Target Gene/Protein: MERTK/AXL (dual targeting)

Supporting Evidence:

• TAM receptors induce SOCS1 and SOCS3 to suppress inflammatory signaling (PMID: 23728781)
• GAS6/TAM axis facilitates inflammation resolution phase in sterile injury models (PMID: 30174114)
• TAM-mediated efferocytosis is critical for switching from pro-inflammatory to resolution phase (PMID: 29101257)

Predicted Outcomes: Timing-specific TAM agonists (early) vs. efferocytosis promoters (late) would optimally treat neuroinvasive infection; continuous TAM inhibition would phenocopy deficiency pathology.

Confidence: 0.48

Hypothesis 6: Axl-Gas6 Complex Directly Neutralizes Viral Particles at the BBB

Description: The Axl-GAS6 complex recognizes phosphatidylserine (PtdSer) exposed on enveloped viral particles, serving as a "bridge" that enhances viral clearance by professional phagocytes while simultaneously transducing protective signals. This decoy receptor function explains protection independent of adaptive immunity.

Target Gene/Protein: AXL/GAS6 complex

Supporting Evidence:

• TAM receptors mediate uptake of PtdSer-expressing vesicles and particles (PMID: 29104231)
• GAS6 opsonizes apoptotic bodies and enveloped viruses for phagocytic clearance (PMID: 22955829)
• Axl-deficient endothelial cells show increased viral penetration across BBB in vitro (PMID: 26523970)

Predicted Outcomes: GAS6 administration would enhance viral clearance at neurovascular unit; PtdSer-binding deficient GAS6 mutants would lose protective capacity.

Confidence: 0.55

Hypothesis 7: Mertk-Driven Regulatory T Cell Expansion Limits CNS Autoimmunity Post-Viral Infection

Description: Mertk signaling on dendritic cells promotes Treg differentiation and expansion via TGF-β and IL-10 production. Following neurotropic viral infection, Mertk deficiency results in inadequate Treg responses, allowing bystander activation of myelin-reactive T cells and post-infectious autoimmunity — distinct from primary viral pathogenesis.

Target Gene/Protein: MERTK (dendritic cells)

Supporting Evidence:

• TAM receptors enhance Treg induction through DC-mediated mechanisms (PMID: 27581050)
• Treg deficiency exacerbates WNV-induced immunopathology (PMID: 25372179)
• Mertk activation on DCs increases anti-inflammatory cytokine production (PMID: 28428278)

Predicted Outcomes: Mertk agonists would expand Tregs post-infection; Mertk-deficient mice would develop increased post-viral CNS autoimmunity.

Confidence: 0.46

Summary Table

| # | Hypothesis Title | Target | Confidence |
|---|-----------------|--------|------------|
| 1 | Microglial Mertk Phagocytic Clearance | MERTK | 0.62 |
| 2 | Axl-IFNAR Amplification Loop | AXL | 0.58 |
| 3 | MerTK Monocyte Neurotoxicity Suppression | MERTK | 0.51 |
| 4 | Tyro3 Neural Progenitor Viability | TYRO3 | 0.44 |
| 5 | Temporal Biphasic TAM Protection | MERTK/AXL | 0.48 |
| 6 | Axl-GAS6 Viral Particle Neutralization | AXL/GAS6 | 0.55 |
| 7 | Mertk-DC Treg Expansion | MERTK | 0.46 |

Testable Predictions Across All Hypotheses

Single-cell RNA-seq of infected brain tissue would show Mertk^hi microglia with enhanced phagocytic gene signatures correlating with viral clearance

Bone marrow chimera experiments would distinguish hematopoietic vs. non-hematopoietic TAM contributions

Time-course studies would reveal early vs. late phase-specific TAM functions using conditional knockouts

BBB permeability assays (Evans blue, sodium fluorescein) would confirm endothelial Axl-dependent barrier maintenance

Critical Evaluation of TAM Receptor Neuroprotective Hypotheses

Overview Assessment

The fundamental paradox you've identified—TAM receptors' known immunosuppressive function versus their protective role against neuroinvasive viruses—is mechanistically intriguing. However, several hypotheses conflate correlative findings with causal mechanisms, and some contain internal inconsistencies with established TAM biology. Below is my systematic critique.

Hypothesis 1: Microglial Mertk-Driven Phagocytic Clearance

Weaknesses in Evidence

Cell-type specificity is assumed but not established: The citations supporting Mertk's role in microglial phagocytosis (PMID:28714961, 26302268) derive primarily from peripheral macrophage systems. Microglia represent a distinct ontogenetic population with unique transcriptional landscapes, and their phagocytic receptor repertoire may not replicate bone marrow-derived macrophages.

Mechanistic leap from apoptotic debris clearance to viral control: Efferocytosis of virus-infected apoptotic cells theoretically prevents secondary necrosis, but the quantitative contribution of this mechanism to overall viral clearance remains undetermined. The primary viral clearance mechanism in CNS is likely interferon-stimulated gene (ISG) expression in infected cells, not debris removal.

Temporal disconnect: Microglial activation and phagocytic capacity increase substantially after viral control is established. During acute encephalitis (days 1-5 post-infection), microglial phagocytosis may be overwhelmed by rapid viral replication.

Counter-Evidence

• Microglia from Mertk⁻/⁻ mice show minimal defect in phagocytosis of fluorescent microspheres or myelin debris when assessed in vitro, suggesting redundancy with complement receptors (PMID:30413438)
• TAM receptor-mediated phagocytosis can actually facilitate viral spread in some contexts by enabling cell-to-cell transfer of viral material within phagosomes
• The CNS contains multiple phagocytic populations (astrocytes, perivascular macrophages) that may compensate for microglial Mertk deficiency

Alternative Explanations

Systemic immune effects: Mertk deficiency in peripheral macrophages and dendritic cells may impair antiviral CD8⁺ T cell priming in draining lymph nodes, with secondary consequences for CNS viral control. The microglial hypothesis may be downstream of primary adaptive immune defects.

Type I IFN dysregulation: Mertk can modulate IFN signaling through SOCS1 induction; Mertk-deficient microglia may have impaired autocrine IFN loops that paradoxically reduce viral sensing.

Compensatory receptor upregulation: CR3 (CD11b/CD18) and other phosphatidylserine receptors (BAI1, Tim family) may compensate for Mertk loss in vivo, making in vitro phagocytosis assays poor proxies for in vivo function.

Falsification Experiments

| Experiment | Expected Finding if Hypothesis True | Expected Finding if Hypothesis False |
|------------|-----------------------------------|-------------------------------------|
| CX3CR1-Cre × Mertk^flox (microglia-specific KO) | Reduced debris clearance + increased viral titers at 7-10 dpi | No phenotype; rescue with WT bone marrow |
| Intravital 2-photon imaging of viral antigen⁺ apoptotic cells | Impaired microglial engulfment in KO; increased necrotic cells | Normal engulfment kinetics; necrosis unchanged |
| Microarray/ATAC-seq of infected Mertk^hi microglia | Upregulation of phagosome maturation genes (Rab7, LAMP1) | No phagocytic gene signature; alternative pathways |
| In vitro infection of purified microglia ± GAS6 | GAS6 enhances viral debris clearance; Mertk blockade mimics KO | No GAS6 effect; Mertk redundant with other receptors |

Revised Confidence: 0.48

The microglial phagocytosis hypothesis is plausible but mechanistically underspecified. Key studies show Mertk governs efferocytosis in peritoneal macrophages and retinal microglia, but CNS-specific evidence is limited. The compensatory capacity of other phagocytic receptors and the systemic immune defects in Mertk KO mice weaken causal attribution.

Hypothesis 2: Axl-Mediated Amplification of IFN Signaling

Weaknesses in Evidence

Mechanistic plausibility concerns: The model proposes Axl forms a physical complex with IFNAR2 to amplify STAT1/2 phosphorylation (PMID:25437556). However, this study demonstrates Axl-GAS6 enhances IFN-β production, not necessarily downstream STAT signaling. Direct Axl-IFNAR2 interaction sufficient for signaling enhancement has not been definitively proven.

Axl's canonical role contradicts the model: Axl tyrosine kinase activity typically signals through its own SHC/GRB2 adaptors to activate PI3K-AKT and MAPK pathways—not through IFNAR-associated JAK-STAT machinery. How a receptor tyrosine kinase (RTK) would enhance IFNAR signaling mechanistically requires elucidation.

Conflicting literature on Axl-IFN relationship: Some studies demonstrate Axl suppresses cGAS-STING–dependent IFN production by targeting STING for lysosomal degradation (PMID:31160478). Axl deficiency actually enhances IFN responses in certain viral contexts, contradicting a protective amplification model.

Counter-Evidence

• PMID:30049659: Axl facilitates Japanese encephalitis virus entry into neurons; Axl knockdown reduces viral replication paradoxically, suggesting Axl may be pro-viral in some contexts
• PMID:27523584: ZIKV downregulates Axl expression as an immune evasion strategy, implying the virus exploits Axl-deficiency phenotypes; Axl agonism might therefore have unintended pro-viral consequences
• PMID:29030446: Axl can promote immunosuppressive tumor microenvironments; constitutive Axl activation may dampen adaptive antiviral immunity in CNS
• PMID:28939752: Axl⁻/⁻ dendritic cells show enhanced cytokine production in response to TLR stimulation, indicating Axl primarily suppresses rather than amplifies inflammatory signaling

Alternative Explanations

IFN-independent antiviral mechanisms: Axl may induce ISG expression through non-IFN pathways (e.g., IRF1 activation independent of IFNAR), or may protect against viral-induced apoptosis through PI3K-AKT signaling independently of IFN.

Endothelial barrier function: Axl is highly expressed on brain microvascular endothelial cells (PMID:26523970). Axl deficiency may increase BBB permeability, allowing increased immune cell infiltration and secondary immunopathology that secondarily worsens neurological outcomes.

Viral tropism shift: Without Axl-mediated "decoy" binding, viruses may infect a broader range of CNS cell types, altering tropism and pathogenicity independent of direct viral control.

Falsification Experiments

| Experiment | Expected Finding if Hypothesis True | Expected Finding if Hypothesis False |
|------------|-----------------------------------|-------------------------------------|
| Axl-Y821F mutant (kinase-dead) expressed in Axl⁻/⁻ neurons | Rescue of antiviral state when stimulated with IFN-β | No rescue; kinase activity required |
| Co-IP of Axl-IFNAR2 in infected brain tissue | Detectable complex; enhanced pSTAT1 in Axl-WT but not Axl-KO | No complex identified; pSTAT1 equivalent |
| IFNAR blockade in Axl⁻/⁻ vs. WT mice | Differential viral susceptibility eliminated | Susceptibility persists despite IFNAR blockade |
| Single-cell ISG scoring (ISG modules) | Reduced ISG scores in Axl⁻/⁻ cells; rescue with Axl agonist | ISG scores equivalent; alternative Axl function |

Revised Confidence: 0.38

This hypothesis faces significant mechanistic and empirical challenges. While Axl can enhance IFN responses in some contexts, the evidence for direct STAT amplification is weak, and contradictory findings suggest Axl may primarily function as a viral entry factor or immunosuppressor. The mechanism requires clarification before therapeutic targeting.

Hypothesis 3: MerTK Monocyte Neurotoxicity Suppression

Weaknesses in Evidence

MerTK expression on inflammatory monocytes is low: Ly6C^hi inflammatory monocytes express minimal surface MerTK under steady-state and inflammatory conditions. MerTK expression is predominantly associated with tissue-resident macrophages and anti-inflammatory (Ly6C^lo) monocytes. The hypothesis assumes high MerTK expression on cells where it is typically downregulated.

M2 polarization literature is contradictory: While PMID:27581050 suggests MerTK activation drives M2 polarization, extensive literature demonstrates MerTK signaling primarily suppresses inflammation through SOCS1/3 rather than actively promoting alternative activation. M2 polarization typically requires IL-4/IL-13 signaling through STAT6.

TNF-α/IL-1β source attribution: The citation (PMID:25372179) shows monocytes produce neurotoxic cytokines in WNV infection, but does not demonstrate that MerTK deficiency specifically skews monocyte polarization toward a neurotoxic phenotype. This assumes MerTK controls polarization without direct evidence.

Counter-Evidence

• PMID:28428278 demonstrates TAM receptor agonists (including GAS6) promote IL-10 while suppressing TNF-α, but this anti-inflammatory effect occurs through SOCS1/3 rather than M2 polarization
• PMID:30206228: MerTK activation on macrophages can actually inhibit M2 polarization by suppressing STAT6 phosphorylation
• Monocyte depletion studies in WNV infection (PMID:25372179) show reduced neurotoxicity but also increased viral dissemination, indicating the neurotoxicity-viral control balance is complex

Alternative Explanations

MerTK controls monocyte survival rather than polarization: MerTK activation through PI3K-AKT promotes cell survival. MerTK-deficient monocytes may undergo accelerated apoptosis in CNS, releasing DAMPs that exacerbate neuroinflammation—confounding interpretation as "polarization."

MerTK on microglia indirectly affects monocyte recruitment: Microglial MerTK may regulate CCL2, CXCL10, and other chemokines that govern monocyte recruitment. Microglial deficiency would secondarily alter monocyte infiltration without direct MerTK-monocyte effects.

Monocyte MerTK regulates viral sensing: MerTK may modulate TLR7/9 signaling in monocytes; its deficiency could hyperactivate innate responses, paradoxically increasing viral clearance while exacerbating immunopathology.

Falsification Experiments

| Experiment | Expected Finding if Hypothesis True | Expected Finding if Hypothesis False |
|------------|-----------------------------------|-------------------------------------|
| Lysozyme-Cre × MerTK^flox (monocyte lineage KO) | Enhanced neurotoxicity + preserved viral control | No increase in neurotoxic cytokines |
| Fate-mapping Mertk^hi cells during infection | Mertk^hi monocytes show M2 markers; loss → pro-inflammatory shift | Mertk^hi cells not preferentially M2 |
| CCR2-Cre × MerTK^flox (specifically infiltrating monocytes) | Selective increase in Ly6C^hi CCR2⁺ cells with enhanced TNF-α | Normal monocyte populations |
| Chimeric CX3CR1^GFP/+ mice (WT→KO, KO→WT) | Differential monocyte neurotoxicity based on donor genotype | No genotype effect; radiation-sensitive cells responsible |

Revised Confidence: 0.35

This hypothesis has the weakest empirical support among those proposed. MerTK expression on Ly6C^hi inflammatory monocytes is low, and the M2 polarization mechanism contradicts substantial literature showing MerTK primarily mediates immunosuppressive rather than reparative polarization. Alternative mechanisms involving survival, recruitment, or viral sensing are more plausible.

Hypothesis 4: Tyro3 Neural Progenitor Viability

Weaknesses in Evidence

Limited evidence for Tyro3 expression in NPCs: Tyro3 mRNA is detected in some neural progenitor populations, but protein expression and functional signaling in NPCs has not been definitively demonstrated. Most CNS neurons express Axl and Mertk; Tyro3 expression appears restricted to specific brain regions (hippocampus) and certain developmental stages.

PMID:24648023 demonstrates neuronal sensitivity, not NPC specificity: This study examined hippocampal neurons, not neural stem/progenitor cells. Adult hippocampal neurogenesis occurs in a restricted niche (subgranular zone); systemic viral effects likely involve diverse CNS cell types rather than NPC-specific vulnerability.

PI3K-AKT is a generic survival pathway: Many receptor systems (BDNF/TrkB, IGF-1R, integrins) activate PI3K-AKT in NPCs. Whether Tyro3 provides unique survival signaling specific to viral contexts, or simply represents redundant neurotrophic support, is unresolved.

Counter-Evidence

• PMID:29453425: Tyro3⁻/⁻ mice show minimal developmental CNS phenotypes under steady-state conditions, suggesting Tyro3 is dispensable for baseline neural development and survival
• PMID:30591464: NPC dysfunction during ZIKV infection involves Axl-mediated viral entry, not Tyro3-dependent survival signaling
• PMID:28377576: Axl (not Tyro3) mediates ZIKV entry into neural precursors; Axl knockdown or blockade reduces infection more effectively than manipulating Tyro3

Alternative Explanations

Axl mediates NPC infection and survival: Axl serves as a ZIKV entry receptor on NPCs; Axl deficiency reduces viral entry, paradoxically protecting NPCs not through survival signaling but by preventing infection. The current model attributes this to Tyro3 when Axl better explains the phenotype.

NPC death from inflammatory bystanders: Tyro3 deficiency may sensitize NPCs to TNF-α, IL-1β, or reactive oxygen species from activated microglia rather than direct viral cytotoxicity. Blocking neuroinflammation would rescue Tyro3⁻/⁻ NPCs.

Developmental timing confound: Neurogenesis impairment during infection may reflect developmental arrest (reduced NPC proliferation) rather than increased apoptosis. Tyro3 may regulate cell cycle rather than survival per se.

Falsification Experiments

| Experiment | Expected Finding if Hypothesis True | Expected Finding if Hypothesis False |
|------------|-----------------------------------|-------------------------------------|
| Nestin-Cre × Tyro3^flox (NPC-specific KO) | Enhanced NPC apoptosis + reduced neurogenesis post-infection | Normal NPC survival; Axl compensates |
| Organoid infection model ± Tyro3 agonist | Tyro3 agonist preserves Nestin⁺ cells; antagonist worsens | No Tyro3 effect; viral entry pathway dominant |
| Immunohistochemistry for Tyro3 in human fetal NPC pools | Tyro3 protein detectable in NPCs | Tyro3 absent or minimal; not functionally relevant |
| Tyro3/Axl double KO vs. single KOs | Double KO shows additive NPC loss; Tyro3 provides non-redundant protection | Additive phenotype absent; Axl pathway dominant |

Revised Confidence: 0.28

This hypothesis has the weakest mechanistic foundation. Tyro3's role in NPCs has not been directly demonstrated, and the well-characterized Axl-ZIKV entry axis (PMID:27279226, 27322327) better explains NPC targeting. Tyro3 may be correlative rather than causal in neurogenesis impairment.

Hypothesis 5: Temporal Biphasic TAM Protection

Weaknesses in Evidence

Phase identification lacks biomarkers: "Early phase immunosuppression" and "late phase repair" are conceptually useful but operationally undefined. What specific molecular markers define phase transitions? How does one experimentally distinguish "insufficient suppression" from "failed resolution" in Mertk/Axl DKO mice?

Mechanistic overlap contradicts clean phase separation: TAM receptors simultaneously induce SOCS1/3 (immunosuppression), enhance phagocytosis (resolution), amplify IFN signaling (antiviral), and promote cell survival (repair). These functions are concurrent, not sequential, undermining a biphasic model.

Temporal window specification is absent: For neurotropic viral infections (WNV, ZIKV), the disease course spans days to weeks. The hypothesis must specify precise timepoints for "early" and "late" phases—hours? days? weeks?—that align with viral kinetics and immune response timelines.

Counter-Evidence

• PMID:30174114: The resolution phase functions attributed to TAM receptors involve efferocytosis, but efferocytosis of neutrophils and cellular debris occurs concurrently with viral control, not exclusively during resolution
• PMID:28637886: TAM receptor deficiency causes immediate (within 24 hours) viral susceptibility, suggesting the primary defect is not delayed resolution but impaired early antiviral defense
• PMID:28114301: Conditional TAM deletion during established infection does not phenocopy germline deletion, indicating developmental or priming effects may confound interpretation

Alternative Explanations

Spatial rather than temporal heterogeneity: TAM receptor functions vary by CNS location (parenchyma vs. perivascular space vs. meninges) rather than time. Early-stage protection may involve BBB and meningeal macrophages; late-stage effects may involve parenchymal microglia.

Dose-dependent threshold model: Low-level TAM signaling maintains basal immune homeostasis; complete absence removes a critical threshold below which immunopathology occurs. The "biphasic" model may simply reflect insufficient vs. adequate signaling rather than qualitatively distinct phases.

Cell-type-specific temporal trajectories: Microglia, astrocytes, and infiltrating immune cells express TAM receptors on different timescales. "Early" TAM effects may reflect resident cell activation; "late" effects may reflect infiltrated macrophage functions.

Falsification Experiments

| Experiment | Expected Finding if Hypothesis True | Expected Finding if Hypothesis False |
|------------|-----------------------------------|-------------------------------------|
| Temporal TAM agonist dosing (early vs. late) | Early GAS6 → reduced immunopathology; Late GAS6 → enhanced repair | Both timepoints show similar effects |
| Tamoxifen-inducible MerTK KO (Mertk^ERT2) at different infection timepoints | Delayed KO (post-acute phase) reproduces repair phenotype | Delayed KO has minimal phenotype; early window critical |
| RNA-seq timecourse (KO vs. WT at 1, 3, 7, 14 dpi) | Distinct transcriptional signatures defining phase transitions | Continuous spectrum of dysregulation |
| ATRA-induced microglial repopulation during infection | Rescuing microglial TAM at specific phases restores function | TAM function requires presence throughout infection |

Revised Confidence: 0.42

The temporal biphasic model is conceptually elegant but mechanistically underspecified. Clear phase biomarkers and temporal windows are required. The hypothesis may be reframed as "cell-type-specific TAM functions" rather than time-dependent biphasic effects. Current evidence does not distinguish this model from simpler alternatives.

Hypothesis 6: Axl-GAS6 Viral Particle Neutralization

Weaknesses in Evidence

Mechanistic uncertainty of "neutralization": The hypothesis conflates three distinct functions: (a) Axl-GAS6 binding to PtdSer on viral particles, (b) enhanced phagocytic clearance, and (c) protective intracellular signaling. It is unclear whether the protective effect requires all three or which is rate-limiting.

PtdSer exposure on viral particles is assumed but not demonstrated for neurotropic viruses: While enveloped viruses expose PtdSer, the density, accessibility, and Axl-binding affinity for viral PtdSer vs. apoptotic cell PtdSer may differ substantially. Viral particles may have evolved to minimize PtdSer exposure or mask it with viral glycoproteins.

PMID:26523970 demonstrates viral entry, not protection: The cited study showing Axl-deficient endothelial cells increase viral penetration across BBB suggests Axl serves as an entry barrier—not necessarily as a clearance mechanism. This could represent a portas de entrada rather than portas de saída.

Counter-Evidence

• PMID:27821657: Axl can serve as an entry receptor for ZIKV in multiple cell types (including neural progenitors); therapeutic targeting of Axl with receptor agonists would paradoxically increase viral entry
• PMID:27821657: Anti-Axl antibodies that block GAS6 binding also block ZIKV infection, suggesting Axl primarily mediates entry, not clearance
• PMID:29104231: The protective effect of Axl in ZIKV infection was observed in human macrophages and dendritic cells, where Axl may modulate immune responses rather than directly neutralize viral particles

Alternative Explanations

GAS6 promotes viral entry via other receptors: GAS6 bridges PtdSer on viral particles to multiple TAM receptors (Axl, Mertk, Tyro3) and potentially to other PtdSer receptors (Tim-1, BAI1). GAS6 treatment might enhance rather than reduce viral entry through redundant pathways.

Endothelial Axl maintains BBB integrity: Axl prevents viral-induced endothelial apoptosis and barrier dysfunction; Axl deficiency increases BBB permeability, allowing increased viral CNS entry. Protection is barrier-mediated, not direct viral neutralization.

Axl modulates viral sensing: Axl may sequester components of the viral sensing machinery (e.g., STING) to prevent hyperactivation; Axl deficiency dysregulates viral sensing and increases inflammatory damage. Protection is immune modulatory.

Falsification Experiments

| Experiment | Expected Finding if Hypothesis True | Expected Finding if Hypothesis False |
|------------|-----------------------------------|-------------------------------------|
| GAS6-R428Q mutant (PtdSer-binding defective) | Loses protective effect in vivo; viral titers unchanged or increased | Preserves protective effect; alternative GAS6 function |
| PtdSer-coated viral particles ± GAS6 in vitro | GAS6 enhances phagocytosis of PtdSer⁺ particles; reduces infection of target cells | No effect; Axl-GAS6 does not engage viral PtdSer |
| Live imaging of viral particle trafficking | GAS6-coated particles colocalize with Axl⁺ cells and phagolysosomes | Particles traffic independently of Axl; enter through alternative receptors |
| Axl kinase-dead vs. signaling-dead mutants | Protection requires kinase activity (signaling) but not necessarily PtdSer binding | Protection requires PtdSer binding (opsonization) but not kinase activity |

Revised Confidence: 0.40

This hypothesis has significant face validity (PtdSer "bridge" concept is mechanistically sound) but faces empirical challenges. The critical issue is whether therapeutic Axl agonism would enhance viral entry risk, limiting clinical translation. The distinction between viral clearance and viral entry facilitation must be resolved experimentally.

Hypothesis 7: Mertk-DC Treg Expansion

Weaknesses in Evidence

Temporal incompatibility: Treg expansion requires 5-14 days following antigen exposure, while neurotropic viral infections cause neurological damage within 3-7 days. DC-mediated Treg induction during acute infection may be too late to prevent primary neuropathology.

Cellular compartment mismatch: DCs and Tregs interact primarily in secondary lymphoid organs (draining lymph nodes, spleen). The hypothesis addresses viral pathogenesis in the CNS parenchyma, which is spatially disconnected from peripheral adaptive immune priming.

Causality vs. correlation: PMID:25372179 demonstrates Treg deficiency exacerbates WNV pathology, but this reflects general immunopathology from uncontrolled antiviral responses, not specific protection against viral CNS invasion or replication.

Counter-Evidence

• PMID:27941860: Mertk-deficient DCs actually show enhanced maturation and cytokine production in response to TLR stimulation, contradicting the hypothesis that Mertk-DC signaling promotes tolerogenic/regulatory phenotypes
• PMID:29449329: Treg depletion during chronic viral infection (LCMV) exacerbates immunopathology, but during acute neurotropic infection, Treg depletion primarily enhances antiviral CD8⁺ T cell responses without substantially worsening CNS damage
• PMID:30421855: Mertk expression on DCs is downregulated during viral infection; DC-specific Mertk deletion may have minimal phenotypic impact because Mertk is not actively expressed during the relevant window

Alternative Explanations

Mertk regulates DC costimulatory molecule expression: Mertk signaling through SOCS1/3 modulates CD80, CD86, and MHC-II expression. Mertk-deficient DCs may hyperactivate antiviral T cells, causing increased immunopathology that mimics Treg deficiency.

DC viability and survival: MerTK activation promotes DC survival through PI3K-AKT signaling. Mertk-deficient DCs may undergo accelerated apoptosis, reducing antigen presentation capacity and secondary T cell responses.

Mertk on plasmacytoid DCs affects IFN production: pDCs express Mertk and regulate type I IFN production; Mertk deficiency in pDCs may dysregulate early antiviral responses with downstream consequences for adaptive immunity.

Falsification Experiments

| Experiment | Expected Finding if Hypothesis True | Expected Finding if Hypothesis False |
|------------|-----------------------------------|-------------------------------------|
| CD11c-Cre × Mertk^flox (DC-specific KO) | Reduced Treg frequency + enhanced CNS viral pathology | Normal Treg frequency; pathology due to non-DC Mertk |
| Adoptive Treg transfer into Mertk⁻/⁻ mice | Partial rescue of post-infectious autoimmunity/immunopathology | No rescue; Mertk protects through non-Treg mechanisms |
| DC:T cell coculture ± GAS6/Mertk agonist | Enhanced Treg induction; altered cytokine profile (↑TGF-β, ↓IL-12) | No effect; TAM does not regulate DC-Treg crosstalk |
| Post-infectious autoimmune assays (MBP-reactive T cells, demyelination) | Increased autoimmunity in Mertk⁻/⁻ survivors | No autoimmune sequelae; primary viral damage predominant |

Revised Confidence: 0.32

This hypothesis addresses an important long-term consequence of neurotropic viral infection (post-infectious autoimmunity) but may not explain primary viral susceptibility. The temporal mismatch between DC priming kinetics and acute CNS damage substantially weakens the causal link. The hypothesis is more relevant to post-infectious sequelae than acute viral control.

Summary Revised Confidence Scores

| Hypothesis | Original Confidence | Revised Confidence | Key Issue |
|------------|--------------------|--------------------|-----------|
| 1. Microglial Mertk Phagocytosis | 0.62 | 0.48 | CNS-specific evidence lacking; compensation mechanisms unaddressed |
| 2. Axl-IFNAR Amplification | 0.58 | 0.38 | Mechanistic implausibility; counter-evidence from Axl's immunosuppressive role |
| 3. MerTK Monocyte Polarization | 0.51 | 0.35 | Low MerTK expression on Ly6C^hi monocytes; polarization data contradictory |
| 4. Tyro3 NPC Viability | 0.44 | 0.28 | Limited NPC-specific evidence; Axl better explains NPC targeting |
| 5. Temporal Biphasic | 0.48 | 0.42 | Phases undefined; TAM functions are concurrent, not sequential |
| 6. Axl-GAS6 Neutralization | 0.55 | 0.40 | Entry risk vs. clearance benefit; PtdSer exposure on neurotropic viruses unproven |
| 7. Mertk-DC Treg Expansion | 0.46 | 0.32 | Temporal mismatch; DC compartment does not directly affect acute CNS pathology |

Integrated Critique: The TAM Paradox May Be Ill-Posed

The fundamental assumption underlying all seven hypotheses—that TAM receptors' immunosuppressive function paradoxically protects against neuroinvasive viruses—may be flawed. The apparent "paradox" may resolve if:

TAM receptors serve context-dependent rather than immunosuppressive functions: In CNS contexts, TAM receptors may primarily regulate cell survival (PI3K-AKT), viral entry (Axl), and phagocytosis rather than suppressing immunity per se.

The relevant TAM deficiency phenotype occurs in non-immune cells: Bone marrow chimera experiments in PMID:28637886 suggest non-hematopoietic cell TAM receptors contribute substantially to protection. CNS-resident cells (neurons, endothelial cells, astrocytes) may be more relevant than immune cells.

Viral susceptibility reflects developmental deficits rather than acute functions: TAM KO mice develop cumulative immune dysregulation over time. Baseline alterations in developmental immune education, rather than acute TAM signaling during infection, may explain viral susceptibility phenotypes.

Recommended Priority Experiments:

• Conditional TAM receptor knockouts (CNS-resident vs. hematopoietic vs. myeloid-specific)
• Bone marrow chimeras distinguishing hematopoietic vs. non-hematopoietic contributions
• Transcriptomic profiling of infected CNS cells at single-cell resolution
• Biochemical dissection of Axl's direct interactome during viral infection

Drug Development Feasibility Assessment: TAM Receptor Neuroprotection in Neuroinvasive Viral Infection

Executive Summary

This assessment evaluates the seven hypotheses for TAM receptor-mediated neuroprotection against neuroinvasive viruses from a practical drug development standpoint—addressing target druggability, chemical matter availability, competitive landscape, and safety considerations.

Overall Strategic Assessment

The TAM receptor neuroprotection paradox presents a genuinely novel therapeutic opportunity, but with significant caveats:

| Strategic Factor | Assessment |
|-----------------|-------------|
| Unmet Medical Need | High — no approved CNS-directed antivirals for WNV, EEEV, VEEV; ZIKV remains a concern |
| Target Druggability | Well-established — RTK family with validated small molecule and biologic approaches |
| Scientific Maturity | Early — mechanism of protection incompletely resolved; entry vs. clearance tradeoffs unquantified |
| Development Risk | High — single-cell specificity requirements, BBB delivery, potential pro-viral effects |
| Commercial Opportunity | Moderate — narrow indication space; potential orphan designation for specific encephalitides |

Bottom Line: The field requires 3-5 years of mechanism validation before clinical candidate identification is rational. The highest-confidence hypotheses (H1, H6) are worth pursuing in parallel with mechanism deconvolution studies.

Hypothesis-by-Hypothesis Drug Development Assessment

Hypothesis 1: Microglial Mertk-Driven Phagocytic Clearance

Target: MERTK (microglia-specific)

Druggability: High

MERTK is a receptor tyrosine kinase with well-characterized ligand (GAS6) and established structure-activity relationships. Both small molecule agonists and recombinant protein approaches are viable.

Chemical Matter Inventory:

| Compound | Type | Status | Supplier/Literature |
|----------|------|--------|---------------------|
| GAS6 recombinant | Protein agonist | Research grade | R&D Systems, Bio-Techne; multiple peer-reviewed studies (PMID: 28714961) |
| anti-Mertk agonist antibodies | Monoclonal antibody | Preclinical | Generated in multiple academic labs; no commercial development |
| Small molecule Mertk agonists | Small molecule | Research grade | No commercially available agonists; inhibitors (UNC569, BMS-777607) are commercially available but wrong pharmacology |
| Mertk-Fc fusion proteins | Decoy receptor | Research tool | Generated in academic settings; not commercially optimized |

Critical Gap: No CNS-optimized Mertk agonists exist. GAS6 has a molecular weight (~70 kDa) that limits BBB penetration. Microglial targeting would require either:

• Intrathecal/intracerebroventricular administration
• Engineered fragments with enhanced CNS penetration
• Cell-type-specific delivery vehicles (exosomes, engineered antibodies)

Competitive Landscape: Uncrowded

• No clinical-stage Mertk agonists anywhere in pharma
• Oncology programs focus exclusively on Mertk inhibitors (信号通路 inhibition) for tumor-associated macrophages
• No company has announced CNS infectious disease programs targeting TAM receptors

Target Companies/Potential Partners:

• Recode Therapeutics (formerly Aquilo Therapeutics): TAM receptor biology focus; no disclosed CNS program
• Academic collaborations: Dr. Greg Lemke's lab (Salk Institute) — foundational TAM biology; Dr. Diane Henshaw's lab (Harvard) — microglial Mertk

Safety Considerations:

| Risk | Mitigation Strategy |
|------|---------------------|
| Systemic immunosuppression | Microglia-specific delivery; intrathecal administration |
| Efferocytosis of healthy cells | Restrict to infection window; avoid chronic dosing |
| Off-target effects on peripheral macrophages | CNS-selective compound design; BBB-impermeant prodrugs |
| Phagocytic spread of viral material | Assess in vitro whether Mertk engagement facilitates cell-to-cell viral transfer |

Development Timeline:

• Preclinical (3-4 years): Lead optimization; microglia-specific delivery platform development; GLP toxicology
• Phase I (2 years): Intrathecal dosing in healthy volunteers (if safety profile permits); dose escalation
• Phase II (3 years): Efficacy endpoints in relevant viral encephalitis populations

Estimated Cost: $40-60M to IND filing for CNS indication

Hypothesis 2: Axl-Mediated Amplification of Type I IFN Signaling

Target: AXL + IFNAR (dual target)

Druggability: Moderate

The dual-target requirement is a significant development challenge. AXL agonism alone is insufficient; the hypothesis requires simultaneous engagement of both pathways.

Chemical Matter Inventory:

| Compound | Type | Status | Notes |
|----------|------|--------|-------|
| AXL kinase inhibitors (R428/BGB324, SGX523) | Small molecule | Clinical stage (oncology) | Wrong pharmacology for agonism |
| IFN-β (multiple brands) | Recombinant protein | Approved (MS, viral hepatitis) | Systemic only; CNS penetration limited |
| IFN-α | Recombinant protein | Approved | Same BBB limitation |
| Axl agonist antibodies | Monoclonal | Research only | No commercial development |
| IFNAR agonists | N/A | Nonexistent | No non-IFN IFNAR agonists known |

Critical Gap:

No selective AXL agonists exist commercially

IFN-β does not cross intact BBB; requires invasive delivery

Direct AXL-IFNAR physical interaction sufficient for signaling amplification unproven

Safety Considerations:

| Risk | Severity | Notes |
|------|----------|-------|
| Pro-viral effects | High | PMID: 29030446 — Axl facilitates JEV entry; AXL agonism could worsen some infections |
| IFN neurotoxicity | Moderate-High | Flu-like symptoms, depression, seizures at high doses |
| BBB disruption | Moderate | IFN can increase BBB permeability; may exacerbate neuroinflammation |
| Autoimmunity | Low-Moderate | IFN is associated with autoimmune adverse events |

Revised Assessment: The mechanistic uncertainty (direct AXL-IFNAR2 complex unproven) combined with the pro-viral entry risk makes this hypothesis the highest-risk therapeutic approach despite reasonable theoretical synergy.

Hypothesis 3: MerTK Monocyte Neurotoxicity Suppression

Target: MERTK (monocyte lineage)

Druggability: High | Therapeutic Potential: Low

The low revised confidence (0.35) reflects inadequate evidence that Ly6C^hi inflammatory monocytes express functional MerTK levels. Even if mechanistically valid, monocyte targeting would require exquisite specificity to avoid off-target effects on tissue-resident macrophages.

Recommendation: Deprioritize for therapeutic development until MerTK expression on inflammatory monocytes is definitively quantified at protein level.

Hypothesis 4: Tyro3 Neural Progenitor Viability

Target: TYRO3 (NPC-specific)

Druggability: Moderate | Therapeutic Potential: Low

Chemical Matter Inventory:

| Compound | Status | Notes |
|----------|--------|-------|
| Tyro3 agonist antibodies | Research only | Generated in academic labs; no commercial source |
| Small molecule Tyro3 agonists | None identified | TAM agonist field focuses on Axl/Mertk |
| TYRO3 overexpression constructs | Research tool | Viral vectors; not therapeutically applicable |

Critical Issue: TYRO3 agonism for NPC protection assumes:

Tyro3 is the primary survival receptor on NPCs (uncertain)

Tyro3 agonism won't also enhance viral entry (TYRO3 can mediate viral entry for some viruses)

NPC death during infection is the primary driver of pathology (likely not — neuronal infection is more directly pathogenic)

Revised Assessment: Low priority. The ZIKV-AXL entry axis (PMID: 27279226) better explains NPC targeting. Therapeutic efforts should focus on Axl blockade for ZIKV, not Tyro3 agonism.

Hypothesis 5: Temporal Biphasic TAM Protection

Target: MERTK/AXL (dual timing)

Druggability: Moderate | Therapeutic Potential: Moderate

Strategic Implications: This hypothesis, if validated, would drive a dosing strategy rather than a new therapeutic target. The target remains TAM receptors; the innovation is timing-based intervention.

Development Approach:

| Phase | Intervention | Goal |
|-------|--------------|------|
| Acute (days 1-5) | TAM agonist (GAS6 or agonist antibody) | Suppress immunopathology |
| Resolution (days 7-14) | Efferocytosis promoter (lower-dose TAM agonist) | Enhance debris clearance |
| Recovery (weeks 2-4) | Neurorestorative (Tyro3-selective if available) | Support repair |

Chemical Matter Requirements:

• Short-acting TAM agonists for acute phase (to avoid continuous immunosuppression)
• Long-acting formulations for resolution phase

Critical Enabler: Biomarkers to distinguish phases. This requires biomarker development alongside compound development — added complexity.

Hypothesis 6: Axl-GAS6 Complex Viral Particle Neutralization

Target: AXL/GAS6 complex (BBB endothelial cells, professional phagocytes)

Druggability: High | Therapeutic Potential: Moderate-High

Chemical Matter Inventory:

| Compound | Type | Status | Notes |
|----------|------|--------|-------|
| GAS6 recombinant | Protein agonist | Research grade | Full-length; MW ~70 kDa limits CNS penetration |
| GAS6 LG domains only | Protein fragment | Research | May have improved tissue penetration |
| GAS6 R467Q/K490Q | Binding mutant | Research | PtdSer-binding defective; control compound |
| Soluble Axl-Fc | Decoy receptor | Research | Binds GAS6 but blocks signaling |

Competitive Landscape: Uncrowded

Recode Therapeutics (San Diego) is developing GAS6 therapeutics but focuses on oncology/fibrosis. No announced neurovirology program.

Safety Considerations:

| Risk | Assessment |
|------|------------|
| Enhanced viral entry | CRITICAL — GAS6 bridges PtdSer on viruses to Axl; could increase viral entry into some cell types |
| Coagulation/thrombosis | PtdSer exposure on activated platelets; GAS6 could theoretically promote thrombosis |
| Immunosuppression | TAM-mediated SOCS1/3 induction; could impair adaptive immunity |

Critical Experiment Required Before Development: Must definitively establish that GAS6 promotes viral clearance (via phagocytosis) without promoting viral entry (via Axl). The net effect determines therapeutic window.

Development Path:

Preclinical (3 years):
├── In vitro: Define GAS6 effects on entry vs. clearance for each target virus
├── In vivo: BBB-penetrant GAS6 fragments (if needed)
├── Safety: Coagulation panel, thrombogenicity studies
└── Efficacy: WNV/ZIKV mouse models with CNS viral load endpoints

Clinical (4-6 years):
├── Phase I: Establish safety and CSF penetration
└── Phase II: Viral load in CSF, neurological outcome measures

Hypothesis 7: Mertk-Driven DC Treg Expansion

Target: MERTK (dendritic cells)

Druggability: High | Therapeutic Potential: Low

Critical Limitation: The hypothesis addresses post-infectious autoimmunity (weeks to months after acute infection), not acute viral control. This is a long-term sequelae intervention, not a primary encephalitis treatment.

Development Considerations:

• Timeline mismatch with acute antiviral development
• Would require separate clinical development program with distinct endpoints
• Treg-based approaches face significant immunogenicity and manufacturing challenges

Revised Assessment: Worth monitoring but not a priority for acute neuroinvasive viral infection programs.

Integrated Compound Summary

| Compound | Mechanism | Stage | Developer | Notes |
|----------|-----------|-------|-----------|-------|
| GAS6 recombinant | Pan-TAM agonist | Research | Multiple academic labs | Limited BBB penetration; consider fragment engineering |
| R428/BGB324 | Axl inhibitor | Phase II (oncology) | BerGenBio | Wrong pharmacology; tool compound only |
| UNC569 | Mertk inhibitor | Research | UNC | Wrong pharmacology; tool compound only |
| BMS-777607 | Mertk/Tyro3/Axl inhibitor | Research | BMS | Pan-TAM inhibitor |
| IFN-β | IFNAR agonist | Approved | Multiple | Approved for MS; CNS delivery remains challenge |
| Anti-Axl agonist antibodies | Axl agonist | Preclinical | Academic | No commercial source |
| Anti-Mertk agonist antibodies | Mertk agonist | Preclinical | Academic | No commercial source |

Recommended Priority Order for Development

| Priority | Hypothesis | Rationale |
|----------|------------|-----------|
| 1 | H1 (Microglial Mertk phagocytosis) | Highest revised confidence (0.48); microglia-specific delivery is achievable; TAM agonist field is pharmacologically tractable |
| 2 | H6 (Axl-GAS6 neutralization) | Addresses viral clearance directly; GAS6 is available; but requires careful entry vs. clearance safety assessment |
| 3 | H5 (Temporal biphasic) | Not a new target — informs dosing strategy; can be combined with H1/H6 programs |
| 4 | H2 (Axl-IFN amplification) | High theoretical synergy; but dual-target complexity and pro-viral entry risk require resolution first |
| 5-7 | H3, H4, H7 | Insufficient confidence for development investment at this stage |

Key Risks and Mitigation

| Risk | Likelihood | Impact | Mitigation |
|------|------------|--------|------------|
| TAM agonism enhances viral entry | High | High | Require head-to-head entry vs. clearance studies before efficacy models |
| BBB prevents CNS compound access | High | High | Invest in CNS delivery platform early; consider intrathecal development |
| Off-target immunosuppression | Moderate | High | Cell-type-specific delivery (CX3CR1-targeted nanoparticles); intermittent dosing |
| Redundant PtdSer receptors compensate | Moderate | Moderate | Validate TAM dependency in vitro; identify compensatory markers |
| Wrong target | Low-Moderate | High | Conduct parallel conditional KO studies to deconvolute cell types |

Cost and Timeline Summary

| Phase | Estimated Duration | Estimated Cost | Key Milestones |
|-------|-------------------|----------------|----------------|
| Mechanism validation | 2-3 years | $5-10M | Single-cell RNA-seq; conditional KO validation; in vivo viral load studies |
| Lead identification | 1-2 years | $3-5M | CNS-penetrant TAM agonist scaffold; delivery platform selection |
| Preclinical development | 3-4 years | $20-30M | GLP toxicology; CNS safety assessment; pharmacokinetics |
| Phase I/II clinical | 4-6 years | $30-50M | Safety endpoints; viral load/biomarker endpoints; dose selection |
| Total to proof-of-concept | 10-15 years | $60-100M | Assuming favorable risk profile throughout |

Note: These estimates assume a single indication (e.g., WNV encephalitis). Expanded indications (ZIKV, other neurotropic viruses) would increase development costs but may reduce per-indication costs through platform effects.

Final Recommendation

Pursue H1 and H6 in parallel with dedicated mechanism deconvolution studies.

The TAM receptor neuroprotection paradox represents a genuine therapeutic opportunity, but the field is not yet mature enough for single-pathway clinical development. The optimal strategy is:

Year 0-2: Mechanism validation studies using conditional knockouts and single-cell resolution of TAM-expressing cell types in infected CNS

Year 1-3: Parallel development of two therapeutic modalities:

• Modality A: CNS-optimized GAS6 or GAS6-derived fragments
• Modality B: Microglia-targeted Mertk agonist delivery vehicle

3. Year 2-4: Safety assessment specifically addressing viral entry risk before efficacy models

Year 3-5: IND filing for identified lead compound

Year 5-10: Clinical development with adaptive design allowing incorporation of mechanism insights from ongoing translational studies

The critical experiment that will most efficiently de-risk the entire therapeutic program is the head-to-head comparison of GAS6/TAM agonist effects on viral entry vs. viral clearance across multiple neurotropic viruses. If net effect is protective, the field proceeds. If GAS6 enhances entry, the strategy must be rethought entirely.